	US 11,951,081 B2
	Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same
Jorge González-Canudas, Mexico City (MX)
Assigned to LABORATORIOS SILANES S.A. DE C.V., Mexico City (MX)
Filed by Laboratorios Silanes S.A. DE C.V., Cdmx (MX)
Filed on Nov. 2, 2021, as Appl. No. 17/516,961.
Application 17/516,961 is a division of application No. 16/337,984, granted, now 11,185,516, previously published as PCT/IB2017/056031, filed on Sep. 29, 2017.
Claims priority of provisional application 62/402,924, filed on Sep. 30, 2016.
Prior Publication US 2022/0296539 A1, Sep. 22, 2022
Int. Cl. A61K 31/155 (2006.01); A61K 9/00 (2006.01); A61K 31/135 (2006.01); A61K 31/17 (2006.01); A61K 31/403 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/495 (2006.01); A61K 31/4985 (2006.01); A61K 31/513 (2006.01); A61K 31/522 (2006.01); A61K 31/573 (2006.01); A61K 38/22 (2006.01); A61K 38/28 (2006.01); A61P 3/10 (2006.01)

CPC A61K 31/155 (2013.01) [A61K 9/0053 (2013.01); A61K 31/135 (2013.01); A61K 31/17 (2013.01); A61K 31/403 (2013.01); A61K 31/4439 (2013.01); A61K 31/444 (2013.01); A61K 31/495 (2013.01); A61K 31/4985 (2013.01); A61K 31/513 (2013.01); A61K 31/522 (2013.01); A61K 31/573 (2013.01); A61K 38/22 (2013.01); A61K 38/28 (2013.01); A61P 3/10 (2018.01)]

18 Claims

1. A method of treating diabetes comprising the step of:

administering to a subject in need thereof a therapeutically effective amount of metformin glycinate in combination with one or more additional antidiabetic agents selected from the group consisting of a sulfonylurea, a thiazolidinedione, a dipeptidyl peptidase 4 (DPP4) inhibitor, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, a glucagon-like peptide-1 (GLP1) receptor agonist, glucagon like peptide-1 (GLP-1), and insulin.